Is GHK-Cu safe for dogs?
The short answer
GHK-Cu used topically is among the lowest-risk options on this site — systemic absorption is minimal and long-term use is generally considered acceptable. Note that despite frequent claims otherwise, there is no canine study behind it: the often-cited Veterinary Surgery paper was conducted in rats. The injectable route carries a genuine, breed-specific hazard: Bedlington Terriers and some Labrador lines carry inherited copper storage disease, and any dog with hepatic impairment handles copper poorly. Baseline and follow-up liver values are the safeguard, and for localised problems the topical route usually makes the injectable question moot.
The critical risks
⚠ Copper storage disease in predisposed breeds
Bedlington Terriers and certain Labrador Retriever lines carry an inherited copper storage disorder. In these dogs the injectable route risks hepatic copper accumulation. Hepatic function must be monitored, and the topical route is strongly preferred.
Additional cautions
Pre-existing hepatic disease
Any dog with known liver disease should avoid the injectable route. Copper handling is a hepatic function and impaired clearance changes the risk calculation entirely.
Breeds that require testing first
These breeds carry a genetic trait that changes how GHK-Cu is handled. Testing must be completed before the first dose.
Labrador Retriever — Copper storage disease in certain Labrador lines
Some Labrador Retriever lines carry an inherited predisposition to hepatic copper accumulation. In these dogs, injectable GHK-Cu introduces a copper load the liver handles poorly. Baseline and follow-up liver values are essential, and the topical route — which produces minimal systemic absorption — is strongly preferred.
Bedlington Terrier — Inherited copper storage disease — GHK-Cu contraindicated by the injectable route
Bedlington Terriers carry an autosomal recessive copper storage disorder caused by a COMMD1 gene deletion, which prevents normal biliary copper excretion and leads to progressive hepatic accumulation and cirrhosis. Injectable GHK-Cu introduces additional copper into a system already unable to clear it and should not be used. Topical application produces minimal systemic absorption and is the only route worth considering, with hepatic monitoring.
What the evidence base actually is
Safety claims are only as good as the studies behind them.
GHK-Cu is a three-amino-acid peptide bound to copper, found naturally in blood plasma at levels that decline with age. Research describes it influencing the expression of several thousand genes involved in tissue remodelling, which is why it appears in both wound-healing and skin and coat contexts. The wound-healing evidence is genuinely strong, but it is rodent and human — no canine study exists, despite the frequently cited paper having appeared in a veterinary journal.
Dosing context
Safety is dose-dependent. These are the figures reported in the source literature.
Small / toy breed
under 22 lb (10 kg)
- Reported dose
- 0.5-1 mg per day injectable, or topical twice daily
- Frequency
- Daily (injectable) / twice daily (topical)
- Duration
- 4-8 weeks injectable, topical ongoing
- Studied for
- Wound healing, skin and coat, post-surgical incisions
Medium breed
22–77 lb (10–35 kg)
- Reported dose
- 1-1.5 mg per day injectable, or topical twice daily
- Frequency
- Daily (injectable) / twice daily (topical)
- Duration
- 4-8 weeks injectable, topical ongoing
- Studied for
- Wound healing, skin and coat, joint support
Large / giant breed
over 77 lb (35 kg)
- Reported dose
- 1.5-2 mg per day injectable, or topical twice daily
- Frequency
- Daily (injectable) / twice daily (topical)
- Duration
- 4-8 weeks injectable, topical ongoing
- Studied for
- Wound healing, post-surgical recovery, chronic dermatologic conditions
See the full GHK-Cu profile for mechanism, protocol and monitoring detail.
Common questions
Is GHK-Cu safe for dogs?+
GHK-Cu used topically is among the lowest-risk options on this site — systemic absorption is minimal and long-term use is generally considered acceptable. Note that despite frequent claims otherwise, there is no canine study behind it: the often-cited Veterinary Surgery paper was conducted in rats. The injectable route carries a genuine, breed-specific hazard: Bedlington Terriers and some Labrador lines carry inherited copper storage disease, and any dog with hepatic impairment handles copper poorly. Baseline and follow-up liver values are the safeguard, and for localised problems the topical route usually makes the injectable question moot.
What are the side effects of GHK-Cu in dogs?+
Copper storage disease in predisposed breeds: Bedlington Terriers and certain Labrador Retriever lines carry an inherited copper storage disorder. In these dogs the injectable route risks hepatic copper accumulation. Hepatic function must be monitored, and the topical route is strongly preferred. Pre-existing hepatic disease: Any dog with known liver disease should avoid the injectable route. Copper handling is a hepatic function and impaired clearance changes the risk calculation entirely.
Can GHK-Cu be given to a dog with cancer?+
No cancer-specific contraindication is established for GHK-Cu in the published literature. Any dog with a diagnosed malignancy should nevertheless have its full protocol reviewed by the veterinarian managing the case, since interactions with active treatment are not well characterised.
Does my dog need testing before starting GHK-Cu?+
Yes, for some dogs. Labrador Retriever, Bedlington Terrier carry a genetic trait that changes how GHK-Cu is handled, and testing must be completed before the first dose. Baseline bloodwork is also standard practice before starting any of the compounds covered on this site.
References
- 1.Canapp SO Jr, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 2003. PMID 14648529
- 2.Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 1993. PMID 8227353
- 3.Pickart L, Vasquez-Soltero JM, Margolina A GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. PMID 26236730
- 4.Pickart L, Margolina A Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018. PMID 29986520
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.